| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Significance of low level infliximab in the absence of anti-infliximab antibodies
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bella Ungar, Adi Anafy, Henit Yanai, Yulia Ron, Miri Yavzori, Orit Picard, Ella Fudim, Ronen Loebstein, Uri Kopylov, Yehuda Chowers, Iris Dotan, Rami Eliakim and Shomron Ben-Horin |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| “Talpiot” Medical Leadership program of the Sheba Medical Center |
to SBH, in part |
| Helmsley Charitable Trust |
to SBH, RE, ID and YC |
|
| Corresponding Author |
Bella Ungar, MD, Department of Gastroenterology, Sheba Medical Center Tel Hashomer and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel. bellageyshis@gmail.com |
| Key Words |
Inflammatory bowel disease; Biologic therapy; Infliximab; Immunology; Drug response |
| Core Tip |
Among patients who lose response to infli?ximab (IFX) 10%-60% have low IFX levels in the absence of antibodies to infliximab (ATI) - double negative (DN) status. We explored the prevalence and the mechanisms responsible for DN status. The preva?lence of DN sera varied with the assay and dilution used. Patients with DN status had shorter survival free of ATI compared with matched controls (p < 0.001). We believe that DN status may result from false negative detection of IFX or ATI by a conventional ELISA assay, suggesting a transitional state of low-level immunogenicity, rather than non-immunological drug clearance. |
| Publish Date |
2015-02-11 17:56 |
| Citation |
Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 2015; 21(6): 1907-1914 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i6/1907.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i6.1907 |
